# A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Source: https://onco.cc/trials/nct06968585/  
OnCo record `nct06968585` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing A166 in HER2-positive breast cancer, active and no longer recruiting.

## Summary

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy is a phase 3 interventional study registered as NCT06968585, led by Sichuan Kelun-Biotech Biopharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase III,Multicenter,Randomised,Open-Label,Active-Controlled Trial of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy. Planned enrolment is 365 participants (actual). The study started in 2023-07-18 and primary completion is expected in 2026-11-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06968585
- Phase: 3
- Setting: A Phase III,Multicenter,Randomized,Open-Label,Active-Controlled Trial of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical
- Enrolled: 365

## Sources

- ClinicalTrials.gov NCT06968585: https://clinicaltrials.gov/study/NCT06968585

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [A166](https://onco.cc/drugs/a166/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)
- key papers: [Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial](https://onco.cc/key-papers/paper-nct06968585-j-clin-oncol-2026/)

---
JSON: https://onco.cc/api/v1/entities/nct06968585.json